PL2571517T3 - Preparaty insuliny o długim działaniu - Google Patents

Preparaty insuliny o długim działaniu

Info

Publication number
PL2571517T3
PL2571517T3 PL11720115T PL11720115T PL2571517T3 PL 2571517 T3 PL2571517 T3 PL 2571517T3 PL 11720115 T PL11720115 T PL 11720115T PL 11720115 T PL11720115 T PL 11720115T PL 2571517 T3 PL2571517 T3 PL 2571517T3
Authority
PL
Poland
Prior art keywords
insulins
long
acting formulations
formulations
acting
Prior art date
Application number
PL11720115T
Other languages
English (en)
Other versions
PL2571517T5 (pl
Inventor
Reinhard Becker
Annke Frick
Peter Boderke
Christiane Fuerst
Werner Mueller
Katrin Tertsch
Ulrich Werner
Petra Loos
Isabell Schoettle
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2571517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of PL2571517T3 publication Critical patent/PL2571517T3/pl
Publication of PL2571517T5 publication Critical patent/PL2571517T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL11720115.2T 2010-05-19 2011-05-18 Preparaty insuliny o długim działaniu PL2571517T5 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10305532 2010-05-19
EP10305780 2010-07-13
EP11305140 2011-02-10
EP11720115.2A EP2571517B9 (en) 2010-05-19 2011-05-18 Long - acting formulations of insulins
PCT/EP2011/058079 WO2011144673A2 (en) 2010-05-19 2011-05-18 Long - acting formulations of insulins

Publications (2)

Publication Number Publication Date
PL2571517T3 true PL2571517T3 (pl) 2018-09-28
PL2571517T5 PL2571517T5 (pl) 2024-12-02

Family

ID=44148980

Family Applications (4)

Application Number Title Priority Date Filing Date
PL11166415T PL2387989T3 (pl) 2010-05-19 2011-05-17 Długodziałające formulacje insuliny
PL14166877T PL2781212T3 (pl) 2010-05-19 2011-05-17 Długodziałające formulacje insuliny
PL20199940.6T PL3824876T3 (pl) 2010-05-19 2011-05-17 Długo działające preparaty insuliny
PL11720115.2T PL2571517T5 (pl) 2010-05-19 2011-05-18 Preparaty insuliny o długim działaniu

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL11166415T PL2387989T3 (pl) 2010-05-19 2011-05-17 Długodziałające formulacje insuliny
PL14166877T PL2781212T3 (pl) 2010-05-19 2011-05-17 Długodziałające formulacje insuliny
PL20199940.6T PL3824876T3 (pl) 2010-05-19 2011-05-17 Długo działające preparaty insuliny

Country Status (44)

Country Link
US (11) US20110301081A1 (pl)
EP (9) EP2387989B1 (pl)
JP (5) JP5269945B2 (pl)
KR (4) KR20170072960A (pl)
CN (5) CN107583038A (pl)
AR (1) AR081200A1 (pl)
AU (1) AU2011202239C1 (pl)
BR (2) BR112012029131B1 (pl)
CA (1) CA2792669C (pl)
CL (1) CL2012003197A1 (pl)
CO (1) CO6640217A2 (pl)
CR (1) CR20120578A (pl)
CY (3) CY1115649T1 (pl)
DK (3) DK2387989T3 (pl)
DO (1) DOP2012000261A (pl)
EC (1) ECSP12012298A (pl)
ES (4) ES2945208T3 (pl)
FI (1) FI2571517T4 (pl)
GT (1) GT201200287A (pl)
HK (4) HK1210435A1 (pl)
HR (3) HRP20181028T2 (pl)
HU (2) HUE039355T2 (pl)
IL (2) IL221964A (pl)
JO (2) JO2944B1 (pl)
LT (2) LT2781212T (pl)
MA (1) MA34224B1 (pl)
MX (2) MX389052B (pl)
MY (1) MY156188A (pl)
NI (1) NI201200152A (pl)
NZ (1) NZ602541A (pl)
PE (2) PE20130511A1 (pl)
PH (3) PH12012501895A1 (pl)
PL (4) PL2387989T3 (pl)
PT (3) PT2781212T (pl)
RS (1) RS53559B1 (pl)
RU (3) RU2564104C2 (pl)
SG (2) SG10201510406YA (pl)
SI (3) SI2387989T1 (pl)
TN (1) TN2012000478A1 (pl)
TR (2) TR201809475T4 (pl)
TW (4) TW201735941A (pl)
UY (1) UY33391A (pl)
WO (1) WO2011144673A2 (pl)
ZA (1) ZA201206998B (pl)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP5950477B2 (ja) 2011-08-10 2016-07-13 アドシア 少なくとも１種の基礎インスリンの注射溶液
FR2984749A1 (fr) * 2011-12-23 2013-06-28 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
WO2013104861A1 (fr) * 2012-01-09 2013-07-18 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
GB2513805B (en) * 2012-04-18 2020-04-01 Waters Technologies Corp Methods for quantifying polypeptides using mass spectrometry
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
US9707275B2 (en) * 2012-12-19 2017-07-18 Wockhardt Limited Stable aqueous composition comprising human insulin or an analogue or derivative thereof
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
JP2016505601A (ja) * 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
US20220202711A1 (en) * 2013-04-03 2022-06-30 Sanofi Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins
EP2983697B1 (en) * 2013-04-03 2018-10-31 Sanofi Treatment of diabetes mellitus by long acting formulations of insulins
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
HUE042796T2 (hu) * 2013-06-17 2019-07-29 Sanofi Aventis Deutschland Rögzített glargin inzulin/lixiszenatid arányú készítmény
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
EP3126346B1 (en) 2014-04-04 2018-07-11 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
CN104688677B (zh) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 一种稳定的甘精胰岛素注射液及其制备方法
CN104688678B (zh) * 2015-02-05 2017-11-17 通化东宝药业股份有限公司 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EA039114B1 (ru) * 2015-11-10 2021-12-06 Санофи-Авентис Дойчланд Гмбх Применение композиции с постоянным соотношением инсулин гларгин/ликсисенатид для лечения сахарного диабета 2 типа
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018055539A1 (en) 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CA3047862A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
DK4019039T3 (da) * 2017-07-27 2024-01-15 Adocia Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning
UY38249A (es) 2018-05-30 2019-12-31 Sanofi Sa Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
CN112566655B (zh) 2018-06-21 2025-11-07 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN113993566A (zh) 2019-05-29 2022-01-28 赛诺菲 药物递送装置
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
PL4069278T3 (pl) * 2019-12-06 2025-10-06 Dr. Mary Morris & Associates, Llc Sposoby i kompozycje do zapobiegania cukrzycy typu 1
BR112022023609A2 (pt) * 2020-05-22 2023-02-07 Hanmi Pharm Ind Co Ltd Formulação líquida de conjugado de ação prolongada de agonista trigonal de glucagon, glp-1 e gip
WO2022002408A1 (en) 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
JP7751603B2 (ja) 2020-07-02 2025-10-08 サノフイ 低減された活性を有するｇｌｐ－１ｒアゴニストペプチド
CN116209675A (zh) * 2020-08-14 2023-06-02 克云生物科技股份公司 提高生物治疗性分子的功效
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CH682806A5 (de) * 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
CH682805A5 (de) * 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
US6978471B1 (en) 1999-05-25 2005-12-20 Thomson Licensing S.A. System for acquiring and processing broadcast programs and program guide data
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
EP1585453A4 (en) 2003-01-21 2007-05-02 Ortho Tain Inc DENTAL APPARATUS, SYSTEM AND METHOD FOR REDUCING PATIENT COOPERATION QUANTITY TO TREAT DENTAL MALOCCLUSION USING THE DENTAL DEVICE
GB0304822D0 (en) * 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
EA200501422A1 (ru) 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
WO2005020927A2 (en) 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
ATE483580T1 (de) * 2003-12-22 2010-10-15 Novo Nordisk As Durchsichtiger, flexibler, undurchlässiger kunststoffbehälter zur lagerung von pharmazeutischen flüssigkeiten
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
JP2008537873A (ja) 2004-03-31 2008-10-02 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
KR20070090036A (ko) 2004-12-22 2007-09-04 센토코 인코포레이티드 Ｇｌｐ-1 작용제, 조성물, 방법 및 용도
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
WO2007038540A1 (en) 2005-09-26 2007-04-05 Medtronic, Inc. Prosthetic cardiac and venous valves
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
MY144556A (en) * 2005-10-24 2011-09-30 Nestec Sa Dietary fiber formulation and method of administration
CN101309668A (zh) 2005-11-30 2008-11-19 健乐克斯医药公司 经口吸收的药物制剂和用药方法
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
CA2652989A1 (en) 2006-06-08 2007-12-13 Diabecore Medical Inc. Derivatized insulin oligomers
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
EP2076242B8 (en) * 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
EP2578677A1 (en) 2007-08-09 2013-04-10 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
JP5710253B2 (ja) 2007-08-13 2015-04-30 ノボ・ノルデイスク・エー／エス 速効型インスリンアナログ
JP5241849B2 (ja) * 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
US20090175840A1 (en) 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
WO2009104199A1 (en) 2008-02-19 2009-08-27 Biocon Limited A method of obtaining purified heterologous insulins expressed in yeast
EP2288918A1 (en) 2008-05-23 2011-03-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist bioassays
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
DE102008053048A1 (de) * 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
EP2395988A2 (en) 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
PL2459171T3 (pl) 2009-07-31 2017-11-30 Sanofi-Aventis Deutschland Gmbh Kompozycja insuliny o długim działaniu
ES2398012T5 (es) 2009-11-13 2020-02-26 Sanofi Aventis Deutschland Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
CN102770153B (zh) 2010-02-22 2014-05-07 卡斯西部储备大学 呈可溶和结晶形式的长效胰岛素类似物制剂
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
TW201141513A (en) 2010-04-14 2011-12-01 Sanofi Aventis Insulin-siRNA conjugates
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
WO2011160066A1 (en) 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN103167878A (zh) 2010-10-27 2013-06-19 诺沃—诺迪斯克有限公司 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
CN103458919A (zh) 2011-02-02 2013-12-18 赛诺菲-安万特德国有限公司 在2型糖尿病患者中预防低血糖症
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract

Also Published As

Publication number Publication date
MA34224B1 (fr) 2013-05-02
EP2387989A3 (en) 2012-04-18
RS53559B1 (sr) 2015-02-27
EP2387989A2 (en) 2011-11-23
IL251318A0 (en) 2017-05-29
JP2018044003A (ja) 2018-03-22
CN104622788A (zh) 2015-05-20
EP2571517A2 (en) 2013-03-27
PE20130511A1 (es) 2013-05-02
US9345750B2 (en) 2016-05-24
ES2690302T5 (es) 2024-12-03
US20150164999A1 (en) 2015-06-18
EP3636250A1 (en) 2020-04-15
FI2571517T4 (fi) 2024-09-20
MX343489B (es) 2016-11-08
PH12012501895A1 (en) 2016-02-03
EP3824876A1 (en) 2021-05-26
CN107583037A (zh) 2018-01-16
IL251318B (en) 2018-12-31
US20200384087A1 (en) 2020-12-10
IL221964A (en) 2017-04-30
HK1202428A1 (en) 2015-10-02
JP2015172068A (ja) 2015-10-01
PL2781212T3 (pl) 2018-08-31
HUE039354T2 (hu) 2018-12-28
WO2011144673A3 (en) 2012-05-03
ES2945208T3 (es) 2023-06-29
EP2571517B2 (en) 2024-06-19
RU2017146048A3 (pl) 2021-07-01
US20110301081A1 (en) 2011-12-08
ES2690302T9 (en) 2025-01-02
RU2564104C2 (ru) 2015-09-27
BR112012029131A2 (pt) 2016-09-13
DK2571517T3 (en) 2018-07-23
EP3424491A1 (en) 2019-01-09
KR101486743B1 (ko) 2015-01-28
TW201735941A (zh) 2017-10-16
AU2011202239A1 (en) 2011-12-08
TW201607552A (zh) 2016-03-01
ES2676401T3 (es) 2018-07-19
PH12015501421A1 (en) 2015-09-07
ZA201206998B (en) 2013-05-29
MX2012011278A (es) 2012-11-06
EP3400931A1 (en) 2018-11-14
DOP2012000261A (es) 2013-01-31
EP4218723A2 (en) 2023-08-02
EP2571517B9 (en) 2024-10-16
US20160339084A1 (en) 2016-11-24
CA2792669C (en) 2015-09-29
HK1248593A1 (zh) 2018-10-19
TW201427684A (zh) 2014-07-16
TW201208695A (en) 2012-03-01
HRP20140860T1 (hr) 2014-10-24
EP3607935A1 (en) 2020-02-12
EP2781212B1 (en) 2018-04-04
SI2571517T1 (en) 2018-08-31
SI2387989T1 (sl) 2014-10-30
KR20130040824A (ko) 2013-04-24
EP2571517B1 (en) 2018-04-04
AR081200A1 (es) 2012-07-04
TR201809514T4 (tr) 2018-07-23
KR20180088752A (ko) 2018-08-06
SG10201510406YA (en) 2016-01-28
ES2690302T3 (es) 2018-11-20
US20190388511A1 (en) 2019-12-26
RU2017146048A (ru) 2019-06-27
PT2571517T (pt) 2018-07-10
CN102319422A (zh) 2012-01-18
HRP20181028T2 (hr) 2025-01-03
PL2571517T5 (pl) 2024-12-02
RU2011119988A (ru) 2012-11-27
KR101989343B1 (ko) 2019-06-14
UY33391A (es) 2011-10-31
TWI469787B (zh) 2015-01-21
PH12019500517A1 (en) 2020-03-02
US20200215163A1 (en) 2020-07-09
MX389052B (es) 2025-03-20
US20190046616A1 (en) 2019-02-14
DK2781212T3 (en) 2018-07-23
HUE039355T2 (hu) 2018-12-28
JP2013147509A (ja) 2013-08-01
EP2387989B1 (en) 2014-07-16
HK1198428A1 (en) 2015-04-24
DK2387989T3 (da) 2014-10-20
BR122019006884B1 (pt) 2022-08-23
BR112012029131B1 (pt) 2020-03-10
US20160228516A1 (en) 2016-08-11
US20120122774A1 (en) 2012-05-17
JOP20150245B1 (ar) 2021-08-17
RU2642662C2 (ru) 2018-01-25
PL3824876T3 (pl) 2024-02-19
US20210308225A1 (en) 2021-10-07
ECSP12012298A (es) 2012-12-28
JP5269945B2 (ja) 2013-08-21
AU2011202239C1 (en) 2017-03-16
JP2020040990A (ja) 2020-03-19
US20140206611A1 (en) 2014-07-24
TR201809475T4 (tr) 2018-07-23
CR20120578A (es) 2013-03-04
CA2792669A1 (en) 2011-11-24
EP3824876B8 (en) 2023-08-02
EP2781212A1 (en) 2014-09-24
HK1210435A1 (zh) 2016-04-22
LT2781212T (lt) 2018-07-25
KR101913672B1 (ko) 2018-11-01
HRP20181028T1 (hr) 2018-08-24
JP6333775B2 (ja) 2018-05-30
JP2011241213A (ja) 2011-12-01
SG185593A1 (en) 2012-12-28
KR20140109515A (ko) 2014-09-15
NZ602541A (en) 2013-11-29
LT2571517T (lt) 2018-07-25
SI2781212T1 (en) 2018-08-31
CY1120407T1 (el) 2019-07-10
GT201200287A (es) 2015-03-09
PT2387989E (pt) 2014-09-15
HRP20181026T1 (hr) 2018-08-24
DK2571517T4 (da) 2024-09-23
HRP20181028T4 (hr) 2024-09-27
TWI496580B (zh) 2015-08-21
KR20170072960A (ko) 2017-06-27
EP4218723A3 (en) 2023-11-08
CN107583038A (zh) 2018-01-16
HK1248592A1 (zh) 2018-10-19
JO2944B1 (en) 2016-03-15
AU2011202239B2 (en) 2012-06-07
MY156188A (en) 2016-01-29
WO2011144673A2 (en) 2011-11-24
CO6640217A2 (es) 2013-03-22
CY1121042T1 (el) 2019-12-11
PE20160781A1 (es) 2016-08-26
EP3824876B1 (en) 2023-02-22
TWI605825B (zh) 2017-11-21
RU2015132860A (ru) 2017-02-09
CL2012003197A1 (es) 2013-01-25
SI2571517T2 (sl) 2024-10-30
CN103948913A (zh) 2014-07-30
MX2019003693A (es) 2019-07-04
PL2387989T3 (pl) 2014-12-31
TN2012000478A1 (en) 2014-04-01
ES2509943T3 (es) 2014-10-20
NI201200152A (es) 2013-01-24
PH12015501421B1 (en) 2015-09-07
CY1115649T1 (el) 2017-01-04
PT2781212T (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
IL251318A0 (en) Long-acting preparations containing insulin
HUE072859T2 (hu) Hosszantartó hatású GLP-1 peptidek alkalmazása
IL223206A0 (en) Vaccine formulations
SI2603232T1 (sl) Stabilne formulacije linaklotida
EP2552210A4 (en) FORMULAS FROM MAZINDOL
PL2407155T3 (pl) Formulacje inekalcytolu
ZA201205646B (en) Spiroindoline compounds for use as anthelminthics
PT3824876T (pt) Formulações de longa ação de insulinas
GB201005587D0 (en) Novel formulations
TWM400763U (en) Improved structure of cold-accumulating cravats
TWM388315U (en) Improved structure of hemoclip
HU1000688D0 (en) Use of trifluoro-phal